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Research
Exposure to environmental estrogens during 
critical developmental windows has well- 
documented adverse consequences on males 
and females of many species, including rodents 
and humans [National Institutes of Health 
(NIH) 1999; Palmlund 1996]. One group 
of environmental endocrine disruptors that is 
currently receiving significant attention is the 
naturally occurring phyto  estrogens (for review, 
see Rozman et al. 2006a, 2006b). These com-
pounds are readily available in the diet, par-
ticularly in soy products (Adlercreutz et al. 
1999; Lapcik et al. 1998; Whitten et al. 1995). 
The major class of phyto  estrogens found in 
soy is isoflavones; the phyto  estrogen in that 
class that has received the most attention is 
genistein (GEN). GEN is primarily present in 
its glycosylated forms, with genistin (GIN), the 
4′-β-d-glucoside, being predominantly found 
in most soy products, including soy-based 
infant formulas, where GIN makes up > 65% 
of the isoflavone content (Setchell et al. 1997). 
Infants consuming soy-based formulas have 
high circulating levels of GEN, the primary 
metabolite and aglycone form of GIN, rang-
ing from 1.4 to 4.5 µM (381–1,224 ng/mL) 
(Setchell et al. 1997); a recent study reported 
the 25th, 50th, and 75th quartiles in serum 
as 405.3, 890.7, and 1455.1 ng/mL (1.5, 3.3, 
and 5.4 µM, respectively) (Cao et al. 2009), 
indicating that GIN is readily absorbed and 
hydrolyzed to the aglycone form, GEN.
Studies using experimental rodent models   
have shown that neonatal exposure to GEN 
by subcutaneous (sc) injections caused adverse 
consequences on the female rodent reproduc-
tive system, including altered ovarian differ-
entiation, altered estrous cyclicity, subfertility/
infertility, and reproductive tract cancer (Chen 
et al. 2007; Delclos et al. 2009; Jefferson et al. 
2002, 2005, 2006; Kouki et al. 2003; Lewis 
et al. 2003; Nagao et al. 2001; National 
Toxicology Program 2008; Newbold et al. 
2001; Nikaido et al. 2004). After treatment 
with 50 mg/kg/day, the maxi  mum serum 
circulating level (Cmax) of GEN was 6.8 µM 
(1,836 ng/mL) (Doerge et al. 2002). Although 
this level of GEN in mouse serum was only 
slightly higher than reported in infants on soy-
based formulas (Cao et al. 2009; Setchell et al. 
1997), we documented adverse effects on the 
reproductive system at this dose and at lower 
doses of 0.5 and 5 mg/kg GEN (Jefferson 
et al. 2002, 2005), suggesting that the levels 
found in human infants consuming soy-based 
infant formulas have the potential to cause 
adverse effects. It was not clear, however, 
whether the route (sc) and form of compound 
(GEN) administered were appropriate for pre-
dicting human health risks.
Because of limited metabolic capacity   
of the neonate, it was hypothesized that GIN 
would not be efficiently hydrolyzed to GEN 
(Rozman et al. 2006a) and, further, that 
phase II metabolism such as glucuronidation 
would also be limited (Coughtrie et al. 1988; 
Doerge et al. 2001; Onishi et al. 1979). Few 
studies have reported exposing neo  natal rodents 
orally to GIN because of their small size; how-
ever, in a pilot study we demon  strated that 
oral GIN elicited estrogenic activity (Jefferson 
et al. 2007). Neonatal mice treated orally on 
days 2–5 with 25 mg/kg GIN showed increased 
uterine wet weight gain similar to mice that 
received 20 mg/kg GEN sc, thus indicating that 
approximately 80% of orally administered GIN 
reached sufficient circulating levels of the active 
compound to elicit a biological effect com-
pared with sc GEN (Jefferson et al. 2007). This 
is important because Rozman et al. (2006a) 
argued that orally administered GIN, the form 
available to infants consuming soy formula, was 
not biologically active as an estrogen and there-
fore could not cause adverse effects associated 
with other environmental estrogens. 
The purpose of the present study was to 
determine neonatal estrogenic activity after 
oral exposure to GIN, as determined by 
increased uterine wet weight and induction of 
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Ba c k g r o u n d: Developmental exposure to environmental estrogens is associated with adverse 
con  sequences later in life. Exposure to genistin (GIN), the glycosylated form of the phytoestrogen 
genistein (GEN) found in soy products, is of concern because approximately 20% of U.S. infants are 
fed soy formula. High circulating levels of GEN have been measured in the serum of these infants, 
indicating that GIN is readily absorbed, hydrolyzed, and circulated.
oBjectives: We investigated whether orally administered GIN is estrogenic in neonatal mice and 
whether it causes adverse effects on the developing female reproductive tract.
Me t h o d s : Female CD-1 mice were treated on postnatal days 1–5 with oral GIN (6.25, 12.5, 25, or 
37.5 mg/kg/day; GEN-equivalent doses), oral GEN (25, 37.5, or 75 mg/kg/day), or subcutaneous 
GEN (12.5, 20, or 25 mg/kg/day). Estrogenic activity was measured on day 5 by determining uterine 
wet weight gain and induction of the estrogen-responsive gene lactoferrin. Vaginal opening, estrous 
cyclicity, fertility, and morphologic alterations in the ovary/reproductive tract were examined.
re s u l t s: Oral GIN elicited an estrogenic response in the neonatal uterus, whereas the response to 
oral GEN was much weaker. Oral GIN altered ovarian differentiation (i.e., multio  ocyte follicles), 
delayed vaginal opening, caused abnormal estrous cycles, decreased fertility, and delayed parturition.
co n c l u s i o n s: Our results support the idea that the dose of the physiologically active compound 
reaching the target tissue, rather than the administered dose or route, is most important in model-
ing chemical exposures. This is particularly true with young animals in which phase II metabo  lism 
capacity is under  developed relative to adults.
key w o r d s : development, diethylstilbestrol, endocrine disruptors, environmental estrogen, isoflavone, 
ovary. Environ Health Perspect 117:1883–1889 (2009).  doi:10.1289/ehp.0900923 available via http://
dx.doi.org/ [Online 27 July 2009]Jefferson et al.
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the estrogen-regulated gene lactoferrin (LF), 
and then compare this response with that of 
sc GEN exposure. Further, we determined 
long-term consequences on the developing 
reproductive system after orally administered 
GIN, including multio  ocyte follicles (MOFs), 
timing of vaginal opening, estrous cyclicity, 
and reproductive function. The findings of 
this study show that oral administration of 
GIN, the route and chemical found in soy 
products, including soy-based infant formulas, 
adversely affects the developing reproductive 
system in mice.
Materials and Methods
Animals. Adult female CD-1 [Crl:CD-1 
(ICR) BR] mice were obtained from Charles 
River Breeding Laboratories (Raleigh, NC) 
and bred to male mice of the same strain at the 
National Institute of Environmental Health 
Sciences (NIEHS). Vaginal plug detection 
was considered day 0 of pregnancy. Pregnant 
mice were individually housed in ventilated 
polysulfone cages (Technoplast, Inc., Exton, 
PA) with hardwood chip bedding under con-
trolled lighting (12/12-hr light/dark cycle) and 
temperature (21–22°C) conditions. Mice were 
fed NIH 31 mouse chow (Zeigler Brothers, 
Gardners, PA)—which was assayed for phyto-
estrogen content as previously described 
(Thigpen et al. 1999)—and provided fresh 
water ad libitum. All animals were treated 
humanely and with regard for alleviation of 
suffering, and all animal procedures complied 
with NIEHS/NIH animal care guidelines.
Female pups were pooled together, sepa-
rated by sex, and then randomly standardized 
to eight female pups per dam; male pups were 
untreated and used as breeders after reaching 
adulthood. Female pups were treated by one of 
two protocols on post  natal days (PNDs) 1–5: 
a) by sc injection with corn oil or GEN (12.5, 
20, or 25 mg/kg/day; 98% pure; Sigma 
Chemical Co., St. Louis, MO) suspended 
in corn oil (0.02 mL/pup); or b) orally with 
corn oil, GEN (25, 37.5, or 75 mg/kg/day), 
or GIN (10, 20, 40, or 60 mg/kg/day; 98% 
pure; Sigma) suspended in corn oil (2.5 µL/g). 
Oral doses were adminis  tered using a pipette 
inserted inside each pup’s mouth. Pups con-
sumed the dose easily and did not show weight 
loss, stress, or any other gross toxic effect. 
Chemical structures of GIN and GEN are 
shown in Figure 1. Structurally, GIN is com-
posed of GEN and a large sugar group that 
accounts for 37.5% of its molecu  lar weight. 
Based on this, we used actual GEN (aglycone) 
equivalents for dosing with GIN; therefore, 
10 mg/kg/day GIN = 6.25 mg/kg/day GEN, 
20 mg/kg/day GIN = 12.5 mg/kg/day GEN, 
40 mg/kg/day GIN = 25 mg/kg/day GEN, 
and 60 mg/kg/day GIN 60 = 37.5 mg/kg/
day GEN. Throughout the remainder of this 
article, we refer to these GEN-equivalent doses 
as GIN 6.25, 12.5, 25, and 37.5 mg/kg.
Uterotropic bioassay for estrogenicity in 
neonates. Female pups were treated with oral 
GIN or GEN or with sc GEN on PNDs 1–5; 
4 hr after the last treatment, individual body 
weights were taken and pups were euthanized 
by decapitation. Uteri were carefully collected 
using an Olympus SZX16 dissecting scope 
(Olympus America, Center Valley, PA), and 
uterine wet weight was obtained (eight mice 
per treatment group). Uterine weight was not 
adjusted for body weight because body weights 
were not significantly different across treat-
ment groups. Uteri were frozen on dry ice and 
stored at –80°C.
RNA was isolated from uteri (minimum 
of four per group) using the RNeasy Mini 
Kit (Qiagen, Valencia, CA) and then reverse 
transcribed into cDNA using the First Strand 
cDNA Synthesis Kit (Invitrogen, Carlsbad, 
CA). We determined lactoferrin (LF) expres-
sion by real-time reverse transcriptase poly-
merase chain reaction (RT-PCR) as verification 
of estrogenic activity, as previously reported 
(Newbold et al. 2007); 18S ribosomal RNA 
was used for normalization. We determined 
expression using the mathematical model 
described by Pfaffl (2001): 
Expression = 2 (Ct18S – CtLF) × 105, 
where Ct is the cycle threshold.
Serum levels of GEN in neonates. Female 
pups were treated orally with GIN 37.5 mg/kg   
or GEN 37.5 mg/kg on PNDs 1–5. On 
PND5 at each time point (0, 0.5, 1, 2, 4, 8, 
24, and 48 hr) after the last treatment, four to 
six individual pups were decapitated and trunk 
blood was collected. After clotting at room 
temperature, serum (20–40 µL) was prepared 
immediately by centrifugation, frozen on dry 
ice, and stored at –80°C. We determined 
total GEN content by liquid chromatography 
with electrospray tandem mass spectrometry 
(LC-ES/MS/MS) after enzymatic deconjuga-
tion and for GEN (aglycone) without decon-
jugation using aliquots of 10 µL as described 
previously (Doerge et al. 2002). The limit of 
detection was approximately 0.03 µM (signal/
noise, 3); the inter- and intra  day precision and 
accuracy were 3–8% and 93–96%, respectively 
(Twaddle et al. 2002). Model-independent 
pharmaco  kinetic analysis was performed as 
previously described (Doerge et al. 2002). 
Levels of daidzein and equol were also evalu-
ated by LC-ES/MS/MS and found to be con-
sistently undetectable (data not shown).
Ovarian histology. To determine effects on 
ovarian development, ovaries were collected 
prepubertally, after secondary follicle forma-
tion but before corpora lutea formation, as 
previously reported (Jefferson et al. 2002). 
Female mice treated orally with GIN (0, 
6.25, 12.5, 25, or 37.5 mg/kg/day) on PNDs 
1–5 were sacrificed at 19 days of age by CO2 
asphyxiation (eight mice per treatment group). 
Ovaries were collected and fixed in 10% cold 
neutral buffered formalin overnight and then 
changed to cold 70% ethanol. Tissues were 
then processed for histology, embedded in 
paraffin, and cut at 5 µm. Three sections from 
each of three different levels for both ovaries 
were scored for the presence and numbers of 
MOFs and any alterations in ovarian histology 
(total of 18 sections scored per mouse).
Vaginal opening and estrous cyclicity. 
Female mice treated orally with GIN (0, 6.25, 
12.5, 25, or 37.5 mg/kg) on PNDs 1–5 were 
weaned at 22 days of age, housed four per 
cage, and followed daily for vaginal opening 
(16 mice per treatment group). At 2 months 
of age, vaginal smears were obtained daily for 
2 weeks from half of the mice in each treat-
ment group (eight mice per group). Smears 
were collected on positively charged slides 
(Superfrost Plus; Fisher Scientific, Pittsburgh, 
PA), sprayed with Spraycyte fixative (Fisher), 
and stained with hematoxylin and eosin 
(Sigma) to determine the stage of the estrous 
cycle, as previously described (Champlin et al. 
1973). Mice with 3 consecutive days in either 
diestrus or estrus were considered to have 
abnormal cycles.
Fertility assessment. At 2, 4, and 6 months 
of age, female mice that were used to determine 
vaginal opening and estrous cyclicity were bred 
to proven control males of the same strain for a 
2-week period (16 mice per treatment group). 
Females were checked in the morning for vagi-
nal plugs, removed from the male cages, and 
individually housed until delivery. All females 
that were not “vaginal plug positive” were 
removed and then returned to the male cages  Figure 1. Chemical structures of GIN (oral exposure) and GEN (sc exposure). MW, molecular weight. 
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in the afternoon for a total of six attempts at 
achieving vaginal plug–positive status. Fertility 
assessment included the following end points: 
number of plug-positive females, number of 
mice with live litters, average number of live 
pups per litter, and time to delivery.
Statistical analysis. The data were analyzed 
using JMP 7 and SAS 9.1 software (both from 
SAS Institute Inc., Cary, NC). For uterine 
wet weight and real-time RT-PCR data, we 
performed analysis of variance, followed by 
Dunnett’s test. For MOFs, estrous cyclicity, 
and fertility end points, statistical significance 
was determined using the non  parametric 
Mann-Whitney tests or Fisher’s exact test, 
as appropriate. The Cochran-Armitage trend 
test was used to test for dose trends in quan-
tal responses such of MOFs. p-Values < 0.05 
were considered statistically significant.
Results
Estrogenic activity in neonates. Female mice 
treated with sc GEN at 20 and 25 mg/kg/day 
had increased uterine wet weights at 5 days of 
age compared with controls (Figure 2A). We 
also observed increased uterine wet weight 
in mice treated orally with GIN at 25 and 
37.5 mg/kg/day (Figure 2A). Compared 
with sc GEN, approximately 20–33% more 
oral GIN was needed to elicit similar uterine 
wet weight increase compared with controls. 
We observed no increase after oral GEN 25 
or 37.5 mg/kg and only a slight increase at 
75 mg/kg/day (Figure 2A), suggesting that 
much more oral GEN is needed to elicit an 
estrogenic response compared with either sc 
GEN or oral GIN.
To investigate functional estrogen activity   
after sc or oral exposures, we determined 
mRNA levels of the estrogen-regulated pro-
tein LF by real-time RT-PCR. Mice treated 
by sc GEN 12.5, 20, and 25 mg/kg showed 
increased LF mRNA compared with controls, 
correlating with increased uterine wet weight 
at higher doses, resulting in higher expression 
of LF (Figure 2B). Oral exposure to GIN 12.5, 
25, and 37.5 mg/kg showed similar increases 
in LF mRNA compared with controls, which 
also correlated with increased uterine wet 
weight (Figure 2B).
Serum levels of GEN in neonates. Figure 3 
shows the total and aglycone levels of GEN 
measured in serum after oral treatment with 
37.5 mg/kg GIN. These data suggest that the 
glucoside moiety of GIN is readily cleaved to 
the aglycone form, GEN, which can either 
be absorbed into the circulation as the agly-
cone (Cmax = 5.6 µM) or conjugated by UDP-
glucuronosyl transferases in the gut and secreted 
as conjugated forms into circulation (total Cmax 
= 19.2 µM). These levels of GEN are higher 
than those previously reported after sc GEN 
50 mg/kg (Cmax = 2.3 µM aglycone and 5.0 µM 
for total) (Doerge et al. 2002). However, the 
dose-adjusted area under the curve (AUC) 
for total GEN is slightly lower after oral GIN 
(83% of sc GEN) and lower than the AUC for 
aglycone adjusted for dose (48% of sc GEN; 
Table 1). These differences are captured by the 
difference in percent aglycone AUC for sc ver-
sus oral administration (22% vs. 13% of total 
AUC), which reflects the bypass of phase II 
conjugation in the gut after injection.
The internal exposures after orally admin-
istered GEN were much lower compared with 
oral GIN, measured either as Cmax (~ 1 µM) 
or as AUC (3.6 µM-hr; Table 1). Therefore, 
it was not surprising that orally administered 
GEN did not result in a robust estrogenic 
response in the neonate; because results of sc 
administration of GEN have been previously 
reported (Doerge et al. 2002), in the present 
study we followed only mice treated by oral 
GIN for ovarian histology, timing of vaginal 
opening, estrous cyclicity, and fertility. 
Ovarian histology. To determine the 
effect of oral GIN on the developing ovary, 
we evaluated the presence of MOFs in imma-
ture mice at 19 days of age. The percentage 
of MOFs increased with dose of oral GIN 
(p < 0.05, Cochran-Armitage trend test) and 
were significantly higher than in controls in 
all dose groups except the lowest dose [see 
Supplemental Material, Figure 1A, available 
online (doi:10.1289/ehp.0900923.S1 via 
http://dx.doi.org/)].
Vaginal opening and estrous cyclicity. Mice 
exposed to the highest dose of GIN (37.5 mg/
kg) had delayed vaginal opening compared 
with their age-matched control counterparts, 
with 50% of the GIN-treated mice achieving 
vaginal opening 2 days later [see Supplemental 
Material, Figure 2 (doi:10.1289/ehp.0900923.
S1)]. In addition, a few mice in the top two 
dose groups did not have definitive vaginal 
opening, even 5 days after the last control 
mouse exhibited opening. Mice in all other 
groups appeared to achieve vaginal opening at 
a similar time as controls.
To determine the effect of oral GIN on 
estrous cyclicity, vaginal smears were taken 
for 2 weeks beginning at 2 months of age. 
None of the mice in the control group had 
abnormal estrous cycles, whereas 38% of GIN 
12.5 mg/kg, 62% of GIN 25 mg/kg, and 88% 
of GIN 37.5 mg/kg mice had abnormal cycles 
(p < 0.001, Cochran-Armitage trend test), and 
the highest two groups had cycles significantly 
different from those of controls [Fisher’s exact 
test, p < 0.05; see Supplemental Material, 
Figure 1B (doi:10.1289/ehp.0900923.S1)]. 
Abnormal cycles exhibited by mice were pre-
dominantly prolonged time in estrus (with 
a few mice exhibiting prolonged time in 
diestrus).
Fertility assessment. The percentage of oral 
GIN-treated females that were vaginal plug 
positive was similar among dose groups at 
2, 4, and 6 months of age [Figure 4; see also 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0900923.S1)]. We observed a significant 
reduction in the number of mice delivering 
live pups after oral exposure to GIN 25.0 
and 37.5 mg/kg at 6 months of age. In addi-
tion to fewer pregnant females, mice that did 
deliver live pups in the GIN 37.5 mg/kg dose 
had fewer pups at 2 and 6 months of age; the 
GIN 25 mg/kg group also had fewer pups at 
6 months of age.
We also combined all the data across the 
time points (Figure 4C, Table 2). The percent-
age of plug-positive females that resulted in 
litters with live pups was significantly reduced 
in the oral GIN 12.5, 25.0, and 37.5 mg/kg 
groups. In addition, the total number of pups 
produced per dam over the three time points 
and the average number of pups per litter were 
Figure 2. Effects of neonatal treatment with GEN and GIN on female mice on PND5. C, corn oil control. 
(A) Uterotropic bioassay after sc or oral GEN or oral GIN; values shown are mean ± SE uterine wet weight 
for each treatment group (n = 8 mice per group). (B) Real-time RT-PCR for LF shown as mean ± SE of LF 
expression normalized to cyclophilin × 10,000. 
*p < 0.05, compared with controls, Dunnett’s test. 
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significantly reduced in the 37.5 mg/kg group 
compared with the control group. The average 
numbers of pups per litter were borderline sig-
nificantly reduced in the 12.5 and 25.0 mg/kg 
GIN groups, as was the total number of pups 
produced in the 12.5 mg/kg group.
The timing of delivery after achieving 
vaginal plug–positive status is summarized 
in Figure 5. All control mice (treated with 
corn oil) delivered their pups early in the 
morning of gestation day (GD) 19, before 
0900 hours. All oral GIN groups had some 
mice that delivered late in the afternoon of 
GD19 (between 1400 and 1800 hours) or 
delivered 1–2 days late, on GD20 or GD21. 
One mouse in the GIN 6.25 mg/kg group was 
visibly pregnant but did not deliver by 2 days 
past expected delivery; after the mouse was 
euthanized, 16 fully formed pups were found 
dead. On-time deliveries were significantly 
reduced after oral GIN 25.0 and 37.5 mg/kg 
at all time points and oral GIN 12.5 mg/kg at 
4 and 6 months of age (p < 0.05, Fisher’s exact 
test). In addition, the percentage of mice with 
on-time deliveries decreased with increasing 
dose and increasing time (p < 0.05, Cochran-
Armitage trend test). Figure 5B shows the per-
centage of mice with late deliveries (afternoon 
or 1–2 days late) and no live pups per treat-
ment group over time. More than half of the 
mice at 4 and 6 months of age in the 12.5, 
25, and 37.5 mg/kg groups had either late 
deliveries or no live pups. We also observed 
this effect in GIN 6.25 mg/kg mice, with 27% 
exhibiting late delivery at 6 months of age. 
After observing this effect at 2 months of age, 
we took some litter weights at 4 and 6 months 
of age and calculated the average pup weight 
per litter. Although there were too few pup 
weights per treatment group per age to evalu-
ate statistically, the averages combined by cate-
gory of delivery time suggest increased pup 
weight with delayed parturition. All litters that 
were on time (regardless of treatment) had an 
average pup weight of 1.64 ± 0.03 g (n = 28 
litters), and litters that were born late in the 
afternoon were no different, with an average 
pup weight of 1.65 ± 0.03 g (n = 8 litters); 
however, litters that were born 1 or 2 days 
late had a significantly increased average pup 
weight of 1.82 ± 0.04 g (n = 7 litters; p < 0.05, 
Student’s t-test).
Discussion
The present study shows that oral exposure to 
GIN, the glycosylated form of GEN found 
in soy products, results in estrogenic activity   
in PND5 female neonates similar to the 
response to sc GEN. We measured estrogenic 
activity by increases in uterine wet weight 
and induction of the estrogen-responsive gene 
LF. This is significant because experimental 
studies using sc exposure have been criticized 
for not modeling oral exposure with respect 
to metabo  lism and kinetics and were thus 
dismissed as offering no value for human risk 
assessment (Rozman et al. 2006a, 2006b). In 
addition, animal studies using oral dosing of 
GEN to nursing dams produced very little 
circulating GEN in neonates, demonstrating 
that indirect exposure through the dam’s milk 
is not sufficient to produce levels of GEN that 
approach levels in human infants consum-
ing soy formula (Doerge et al. 2006; Lewis 
et al. 2003). Perinatal deficiencies in phase II 
conjugating activity have also been shown 
to play a major role in determining inter-
nal exposures of rodent fetuses and neonates 
to the active aglycone form (GEN) (Doerge 
et al. 2001, 2002). Therefore, questions of 
relative bioavailability of aglycone versus glu-
coside forms of isoflavones persist, particularly 
because soy-based foods and formula con-
tain predominately glucosides (Rozman et al. 
2006a, 2006b).
The relative bioavailability of isoflavone 
glucosides versus aglycones has been studied 
extensively in rodents and humans, but results 
have conflicted (Izumi et al. 2000; King et al. 
1996; Kwon et al. 2007; Richelle et al. 2002; 
Rufer et al. 2008; Sepehr et al. 2007; Setchell 
et al. 2001; Steensma et al. 2006; Zubik and 
Meydani 2003). It is generally accepted that 
the aglycone form of isoflavones has the high-
est estrogenic activity. However, glucosides 
are quickly hydrolyzed to produce the agly-
cone form, so administration of either the 
glucoside or aglycone leads to absorption of 
the biologically active aglycone. Thus, expo-
sure to GEN is theoretically the sum of the 
aglycone and respective glucoside concen-
trations converted on the basis of molecular 
weight (Rozman et al. 2006a). Absorption 
of GIN has been demon  strated by showing 
glucuronidated metabolites of GEN and other 
GEN metabolites in urine of infants fed soy-
based formulas (Hoey et al. 2004). Our study 
confirms that oral GIN is rapidly hydrolyzed 
and absorbed into neonatal circulation, which 
is similar to metabolism in human infants 
because high circulating levels of GEN are 
seen after oral ingestion of soy-based infant 
formulas containing predominantly GIN.
We compared internal exposures to GEN 
from oral GIN and GEN in the present study 
with results for sc GEN from our previous 
study (Doerge et al. 2002). The dose-adjusted 
AUCs for aglycone and total GEN for oral 
GIN and sc GEN were remarkably similar 
(Table 1). The dose-adjusted AUC for GEN 
aglycone after oral GIN were approximately 
half those for sc GEN, which reflected the 
difference in percent aglycone (22% for sc 
GEN and 13% for oral GIN). Despite this 
difference, similar magnitudes of effects were 
Table 1. Comparison of serum circulating levels of GEN after sc or oral GEN or oral GIN exposure.
Treatment (mg/kg) 
Total GEN Aglycone
AUC
Dose corrected 
(AUC/dose) Percent sc AUC
Dose corrected 
(AUC/dose) Percent sc
sc injection
  GEN 50a 147 2.9 100 33 0.66 100
Oral exposure
  GIN 37.5  90.4 2.4 83 12.1 0.32 48
  GEN 37.5 12.8 0.34 12 3.6 0.10 15
aData from Doerge et al. (2002) were adjusted for the dose differences in the present study.
Figure 4. Fertility assessment of mice treated neonatally with oral GIN. C, corn oil control. (A) Percentage of vaginal plug–positive mice delivering live pups by age 
(2, 4, and 6 months). (B) Number of live pups per litter (mean ± SE) by age (2, 4, and 6 months). (C) Percentage of mice delivering live pups for all ages combined 
(mean ± SE). 
*p < 0.05, compared with controls by Fisher’s exact test. **p < 0.05, compared with controls by Mann-Whitney test.
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observed on uterine weight gain, ovary histol-
ogy, estrous cyclicity, and fertility. The 50% 
reduction in aglycone after oral GIN com-
pared with sc GEN, with only a 20% reduc-
tion in uterine weight gain, poses interesting 
questions about the dynamics of circulating 
levels of GEN and estrogenic activity in tar-
get tissues. Whether the peak concentration 
of GEN or the total exposure to GEN (e.g., 
AUC) or some combination of the two is 
the driving factor for estrogenic activity is 
unknown, but the present data suggest that 
both might be important. In addition, the 
glycosylated form can be passively transported 
across the small intestinal membrane and 
enter circulation by the sodium-dependent 
glucose transporter (SGLT1), unlike the 
mechanism by which the aglycone form is 
absorbed (i.e., passive diffusion) (Kwon et al. 
2007). Detailed information on the metabo-
lism, transport, and absorption of these com-
pounds in neonates is necessary to further 
understand these results. The lack of measur-
able levels of daidzein or equol in serum elimi-
nates those compounds as potential sources of 
estrogenic activity in this model.
Oral exposure to GEN, which has known 
estrogenic activity in the human adult (Setchell 
et al. 2001) and in pre  pubertal and mature 
rodents (Diel et al. 2004; van Meeuwen et al. 
2007), does not have a robust estrogenic activ-
ity in the mouse neonate. In the uterotropic 
bioassay, the highest dose of oral GEN was 
75 mg/kg/day, twice the sc GEN or oral GIN 
dose, yet there was only a slight increase in 
estrogenic activity in the mouse neonate. 
Serum circulating levels of GEN after oral 
exposure to GEN support this lack of biologi-
cal effect, with very little GEN found in the 
circulation (only 12% of the sc dose). Lewis 
et al. (2003) demonstrated similar results in 
7 rats. The total AUC for the oral route was 
approximately 10 times less than the sc treat-
ment, meaning the oral route resulted in only 
9% of the circulating levels compared with the 
sc route. 
Although many studies have described 
a role for phytoestrogens, such as GEN, in 
influencing hormone-dependent states in 
adults, there is limited information, espe-
cially regarding long-term effects, on infant 
exposure to soy-based formulas or prod-
ucts. In an epidemiologic study, Cruz et al. 
(1994) reported increased cholesterol syn-
thesis rates in human infants fed soy-based 
formulas. Strom et al. (2001) concluded that 
there was no statistically significant differ-
ence in > 30 outcomes meas  ured in young 
adult women and men (20–34 years of age) 
who were fed soy-based formula or cow-based 
formula as infants. However, in women fed 
soy-based formula, these authors found a 
significant increase in the number of twin 
births, duration of the menstrual cycle, and 
pain associated with the cycle, despite the 
small cohort size (129 soy-based formula–
fed women vs. 269 cow-based formula–fed 
women). A recent study of human infants 
fed soy formula, cow milk formula, or breast 
milk, Bernbaum et al. (2008) found that 
female infants fed soy formula have re-estro-
genization of vaginal cells at 6 months of age; 
this effect was not observed in the two non  soy 
groups. In another recent epidemiology study, 
Zung et al. (2008) reported that breast tissue 
is more prevalent in the second year of life 
in female infants fed soy-based formula than 
in infants who were breast-fed or fed dairy-
based formula. These studies support the idea 
that soy-based infant formulas exert biological 
effects, including estrogenic activity.
The present study clearly demonstrates 
that oral exposure to GIN has adverse con-
sequences on the female reproductive system 
when exposure occurs during neonatal life. 
Furthermore, these effects are similar to sc GEN 
at similar doses (Jefferson et al. 2005). For com-
parison, the incidence of MOFs after exposure 
to oral GIN is similar to that after sc GEN, 
with 37.5% after oral GIN 6.25 mg/kg, 25% 
after sc GEN 5 mg/kg, and 75% after both 
oral GIN 37.5 mg/kg and sc GEN 50 mg/kg.   
Disruptions in estrous cyclicity were also simi-
lar after both treatment routes; 88% of the 
mice in both sc GEN 50 mg/kg and oral GIN 
37.5 mg/kg groups exhibited abnormal cycles. 
We recently demonstrated that the major con-
tribution to infertility in neonatal GEN-treated 
mice is the oviductal and uterine environment 
(Jefferson et al. 2009). During the preimplan-
tation period, half of the embryos were lost 
before the four-cell stage in the oviduct, and 
the other half were unable to develop properly 
in the uterus, leading to complete infertility. 
Table 2. Statistical analysis of fertility end points after oral exposure to GIN (all ages combined).
Outcome, GIN dose (mg/kg) No. Mean ± SE
Mann-Whitney 
p-value
No. of litters with live pups per dam
0 15 1.8 ± 0.2
6.25 14 1.9 ± 0.2 0.6192
12.5 15 1.4 ± 0.2 0.1114
25.0 15 1.6 ± 0.2 0.3326
37.5 12 1.3 ± 0.2 0.0631
Percent plug positive with live pups
0 15 100.0 ± 0.0
6.25 14 89.3 ± 7.7 0.2241
12.5 15 84.4 ± 7.7 0.0498
25.0 15 66.7 ± 8.9 0.0004
37.5 12 63.9 ± 11.0 0.0009
Total no. of live pups per dam
0 15 23.5 ± 2.6
6.25 13 26.5 ± 2.6 0.7974
12.5 14 17.9 ± 2.2 0.0570
25.0 13 21.2 ± 2.1 0.3882
37.5 10 13.8 ± 1.9 0.0040
Average no. of live pups per litter
0 15 13.3 ± 0.5
6.25 13 13.2 ± 0.4 0.3966
12.5 14 12.0 ± 0.8 0.0540
25.0 13 11.8 ± 0.8 0.0597
37.5 10 9.3 ± 1.0 0.0007
End points for each mouse (all three breeding ages) were combined to examine the overall effect on fertility (number of 
mice with litters out of 16).
Figure 5. Timing of delivery of live pups. C, corn oil control. (A) Percentage of vaginal plug–positive mice 
delivering on time for each group by age (2, 4, and 6 months). (B) Percentage of mice per treatment group by 
age (2, 4, and 6 months) that delivered in the late afternoon or 1–2 days late, or that delivered no live pups. 
*p < 0.05 compared with controls by Fisher’s exact test.
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Although we did not see complete infertility 
at any dose examined in the present study, 
observed reduced fertility may result from an 
insufficient uterine environment. Interestingly, 
oral GIN 12.5 mg/kg did not exhibit an estro-
genic response in the uterus on PND5, yet 
adverse effects on the reproductive system were 
seen later in life. Further studies are under way 
to elucidate mechanisms involved in decreased 
embryo survival and how developmental expo-
sure to estrogenic chemicals may permanently 
alter gene expression necessary for maintaining 
pregnancy.
Delayed parturition was another impor-
tant finding in the present study. The bio-
logical signals for parturition are not fully 
understood, but several factors, including 
progesterone levels, placental prostaglandins, 
and uterine oxytocin receptors, have been 
identified as playing roles (Cook et al. 2003). 
Thus, potential reasons for late parturition in 
neonatal GIN-exposed mice include lack of 
signaling from the pup (e.g., prostaglandins), 
elevated progesterone during late pregnancy, 
or lack of response or signaling from the 
uterus (e.g., oxytocin receptors) (Cook et al. 
2003). Because our previous study showed 
that high doses of sc GEN render the uterus 
incapable of supporting pregnancy, it seems 
reasonable that lower doses might also impair 
uterine signaling. Studies are under way to 
understand mechanism(s) responsible for late 
parturition in these mice.
Although care must be taken in extrapolat-
ing data from rodents to humans, important 
information can be gained from experimental 
animal studies. In summary, our study demon-
strates that exposure to oral GIN during 
neonatal development results in adverse conse-
quences in the adult female mouse reproduc-
tive system. Reduced fertility is seen at GIN 
doses of 12.5, 25, and 37.5 mg/kg. By com-
parison, estimated human infant consump-
tion is 6–11 mg/kg isoflavones and 4–7 mg/kg 
GEN (Setchell et al. 1997, 1998). Although 
the doses used in our study are slightly higher, 
similar circulating concentrations of total 
GEN resulted in mice and humans. To date, 
the pharmaco  kinetics of GEN in the serum of 
infants on soy formulas has not been accurately 
evaluated; only single-point estimates of the 
steady-state concentration measured at some 
unknown time since last feeding have been 
evaluated [e.g., 2.5 µM (675 ng/mL) mean 
total GEN in plasma (Setchell et al. 1997), 
3.6 µM (972 ng/mL) median total GEN in 
whole blood (Cao et al. 2009)]. Data on adult 
human pharmaco  kinetics suggest that these 
steady-state estimates are probably much lower 
than peak levels of GEN. The small margin of 
difference between circulating GEN levels in 
infants consuming soy-based infant formula 
and the levels in neo  natal mice that we found 
to produce significant increases in reproductive 
toxicity suggest that risks to reproductive 
health should be carefully considered, espe-
cially because an estimated 20–25% of infants 
in the United States consume soy-based infant 
formulas and the Committee on Nutrition of 
the American Academy of Pediatrics found 
“very limited indications for its use” (Bhatia 
and Greer 2008). Thus, further studies on 
reproductive end points in the human popula-
tion are warranted. Our data also show that 
peri  natal deficiencies in metabolism after oral 
exposure to GEN can affect internal exposures 
in ways similar to that of injection, so only the 
dose of the active chemical that reaches the 
target tissue is important. The present study 
further validates the use of sc-injected GEN as 
a suitable model for oral exposure to GIN in 
neonatal mice.
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